遠大醫藥(00512.HK):集團泌尿系統腫瘤早檢產品在中國大陸實現首張商業化處方落地
格隆匯4月27日丨遠大醫藥(00512.HK)公告,近日,集團核藥抗腫瘤診療板塊與金橡醫學合作開發的泌尿系統腫瘤早檢產品優愛®的首張商業化處方在上海復旦大學附屬華東醫院落地,標誌着我國目前唯一獲批上市的甲基化+基因突變雙機制的尿路上皮癌早檢產品正式進入臨牀應用,爲中國患者提供更精準的無創腫瘤診斷服務。
通過與金橡醫學的合作,集團將以泌尿系統腫瘤精準診斷市場爲切入點,強化構建全方位、多維度的泌尿系統產品市場營銷體系,充分整合資源、優化渠道佈局、強化品牌建設,爲研發管線中放射性診療產品等泌尿系統產品的商業化奠定堅實基礎。此外,優愛/優護系列產品將會與本集團精準診療一體化核藥產品形成多樣化的產品組合,可全方位滿足不同泌尿系統腫瘤患者的早檢查、早診斷、療效監控及治療後復發監測等全病程管理的臨牀需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.